FDA
-
-
-
-
-
-
-
Cocrystal begins Phase 1b norovirus trial at Emory University
-
-
-
-
-
-
-
Cocrystal Pharma presents CDI-988 oral norovirus antiviral data at conference
-
-
-
-
-
-
-
Cocrystal Pharma’s Novel Norovirus Antiviral to be Presented at Department of Defense Medical Conference
-
-
-
-
-
-
-
Noble Capital Reiterates Outperform Rating on Cocrystal Pharma (COCP)
-
-
-
-
-
-
-
Cocrystal Pharma Reports Second Quarter 2023 Financial Results and Provides Updates on its Antiviral Drug Development Programs
-
-
-
-
-
-
-
Cocrystal Pharma Reports Second Quarter 2022 Financial Results and Provides Updates on its Antiviral Development Programs
-
-
-
-
-
-
-
Cocrystal Pharma to Participate in Upcoming Investment Conferences
-
329,911 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

